FIELD: medicine.
SUBSTANCE: group of inventions refers to recurrent and refractory cancer treatment. Disclosed is the use of a composition comprising an antibody molecule which specifically binds to an antigen on a B cell surface and has an Fc domain capable of binding FcγRIIb in a subject having B-cells, expressing FcγRIIb, in combination with an agent which prevents or reduces binding of FcγRIIb presented on the surface of B-cell, with Fc-domain of this antibody molecule, and which prevents or reduces internalization of this antibody molecule into B-cell, for treating recurrent B-cell cancer and/or refractory B-cell cancer resistant to said antibody in a subject having B-cells expressing FcγRIIb. Also disclosed are use of the composition for producing a drug and a method of treating recurrent B-cell cancer and/or refractory B-cell cancer.
EFFECT: group of inventions provides effective treatment for recurrent cancers and/or refractory cancer.
42 cl, 28 dwg, 8 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY COMBINATION AND ITS USE | 2019 |
|
RU2800035C2 |
| BIOLOGICAL MATERIALS AND THEIR APPLICATION METHODS | 2011 |
|
RU2769949C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | 2015 |
|
RU2670147C1 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
